Insight Molecular Diagnostics (IMDX) Current Leases (2016 - 2023)

Insight Molecular Diagnostics (IMDX) posted Current Leases of $628000.0 for Q4 2023, up 156.33% sequentially from $245000.0 in Q2 2019.

Insight Molecular Diagnostics (IMDX) Current Leases (2016 - 2023) Analysis & Trends

Insight Molecular Diagnostics (IMDX) has 5 years of Current Leases data on file, last reported at $628000.0 in Q4 2023.

Quarterly Current Leases changed N/A year-over-year to $628000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $628000.0 (changed N/A YoY) and the FY2023 annual result came in at $628000.0, changed N/A from the prior year.
Current Leases rose to $628000.0 in Q4 2023 per IMDX's latest filing, from $245000.0 in the prior quarter.
The five-year high for Current Leases was $628000.0 in Q4 2023, with the low at $245000.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Waters	31,055.11 Bn	31,054.65 Bn	1.11 Bn	53.00 Mn
2	Thermo Fisher Scientific	191.02 Bn	187.77 Bn	7.74 Bn	-
3	Danaher	137.16 Bn	131.47 Bn	3.59 Bn	-
4	Idexx Laboratories	42.82 Bn	42.62 Bn	722.74 Mn	-
5	Natera	39.09 Bn	37.99 Bn	696.04 Mn	-
6	Agilent Technologies	37.61 Bn	35.81 Bn	990.00 Mn	-
7	Iqvia Holdings	34.23 Bn	32.25 Bn	1.36 Bn	-
8	Illumina	28.14 Bn	26.98 Bn	721.00 Mn	-
9	Mettler Toledo International	26.40 Bn	26.33 Bn	555.82 Mn	-
10	Insight Molecular Diagnostics	196.41 Mn	167.48 Mn	15,000.00	-

Download Data